Explore

Trendline Trendline
Parabilis Biotech Aims for $476 Million IPO to Advance Cancer Treatment

Parabilis Biotech Aims for $476 Million IPO to Advance Cancer Treatment

Parabilis Biotech Aims for $476 Million IPO to Advance Cancer Treatment
Trendline Trendline
SpaceX Sets $135 IPO Price, Aiming for $1.77 Trillion Valuation

SpaceX Sets $135 IPO Price, Aiming for $1.77 Trillion Valuation

SpaceX Sets $135 IPO Price, Aiming for $1.77 Trillion Valuation
Trendline Trendline
Quantinuum's IPO Raises $1.68 Billion, Highlights Quantum Computing's Market Potential

Quantinuum's IPO Raises $1.68 Billion, Highlights Quantum Computing's Market Potential

Quantinuum's IPO Raises $1.68 Billion, Highlights Quantum Computing's Market Potential
Trendline Trendline
Alkermes to Engage in Goldman Sachs Healthcare Conference, Highlighting Neuroscience Innovations

Alkermes to Engage in Goldman Sachs Healthcare Conference, Highlighting Neuroscience Innovations

Alkermes to Engage in Goldman Sachs Healthcare Conference, Highlighting Neuroscience Innovations
Reuters Reuters
Honeywell's Quantinuum heads for Nasdaq debut as quantum computing gains momentum

Honeywell's Quantinuum heads for Nasdaq debut as quantum computing gains momentum

By Prakhar Srivastava and Pritam Biswas June 4 (Reuters) - Honeywell's Quantinuum is set to make its U.S. market debut later on Thursday, after strong investor interest helped the quantum computing company raise $1.68 billion in an upsized initial public offering.
Rapid Read Rapid Read
Legend Biotech's CAR T Therapy Shows 100% Response Rate in Lymphoma Study

Legend Biotech's CAR T Therapy Shows 100% Response Rate in Lymphoma Study

Legend Biotech's CAR T therapy, LB2501, has achieved a 100% response rate in a Phase 1 study of non-Hodgkin lymphoma. All six patients treated with the therapy responded, with five achieving complete remission. The study's results position Legend Biotech as a potential takeover target in the competitive CAR T market. The therapy demonstrated a favorable safety profile, with no dose-limiting toxicities or serious adverse events reported. The trial is ongoing, with further data expected in the coming years.
Reuters Reuters
SpaceX will disrupt $1.6 trillion US communications industry, Oppenheimer says

SpaceX will disrupt $1.6 trillion US communications industry, Oppenheimer says

By Kanchana Chakravarty June 3 (Reuters) - SpaceX will disrupt the $1.6 trillion U.S. communications industry as the Elon Musk-led company's satellite broadband unit Starlink expands, Oppenheimer said in a note on Wednesday, adding that legacy broadband providers like AT&T may be most at risk.
Reuters Reuters
Nasdaq futures lead declines after Broadcom drop

Nasdaq futures lead declines after Broadcom drop

June 4 (Reuters) - S&P 500 and Nasdaq 100 futures fell on Thursday, as Broadcom's revenue miss pressured chip stocks, while equity investors took a breather after a strong rally to record highs.
Reuters Reuters
Goldman Sachs expects SpaceX's AI revenue to surge 100-fold by 2030, FT reports

Goldman Sachs expects SpaceX's AI revenue to surge 100-fold by 2030, FT reports

June 4 (Reuters) - Goldman Sachs expects revenue from SpaceX's AI division to surge to $322 billion by 2030, up from $3.2 billion in 2025, according to the Wall Street bank's forecasts shared with a potential investor, the Financial Times reported on Thursday. 
Trendline Trendline
Puma Biotechnology Grants Inducement Awards to New Employees Under Nasdaq Rule

Puma Biotechnology Grants Inducement Awards to New Employees Under Nasdaq Rule

Puma Biotechnology Grants Inducement Awards to New Employees Under Nasdaq Rule
Trendline Trendline
Rallybio and Avenzo Therapeutics Announce Merger to Advance Oncology Therapies

Rallybio and Avenzo Therapeutics Announce Merger to Advance Oncology Therapies

Rallybio and Avenzo Therapeutics Announce Merger to Advance Oncology Therapies
Reuters Reuters
John Delaney's Forbright targets $994 million valuation in US IPO

John Delaney's Forbright targets $994 million valuation in US IPO

By Arasu Kannagi Basil June 2 (Reuters) - Forbright, founded by former U.S. Representative John Delaney, is targeting a valuation of up to $993.8 million in its U.S. initial public offering, as a strong run of ‌new listings by U.S. banks extends into 2026.